Hiloprobe AB has developed a superior method of diagnosing and prognosing patients with colorectal cancer after surgery. Their innovative clinical tool – the ColoNode is far more accurate than current standard procedures, opening up the possibility of personalized medicine within the colorectal cancer field.
Eirium AB was founded in 2012 as a spin-off company from Umeå University, Sweden. The vision of the company was to develop novel antiviral therapies to address an unmet medical need – a treatment for immuno-compromised patients. The company is currently on hold.
Fredrik Elgh and Jonathan Gilthorpe identified a novel antiviral activity against the herpes virus that targets the early stages of viral infection. They have explored this further to develop an antiviral drug that can be used to treat herpes virus infections more efficiently and help overcome antiviral resistance.
The company has developed a unique and patented probe and method, Onzurf, which can be used to monitor the status of bodily organs from the surface of the organ in question. The probe provides critical life-saving information for patients, and saves resources for the health care sector.
Nordic Biomarker AB – a manufacturer of latex reagents for coagulation and clinical chemistry analyzers
Nordic Biomarker was founded in 2007 by the biochemist Dr Göran Aronsson and the clinical biochemist Dr Gunnar Pohl. Their business idea didn’t directly come from their research at the time at Umeå University, rather from a clear customer need that they identified after their research period. Today, Nordic Biomarker has grown to 20 employees, has a turnover of SEK 40 million with good profitability, and has customers all over the world.
HILICON is a world leading company in developing and manufacturing chromatography products for HILIC (hydrophilic interaction liquid chromatography) separation of polar and hydrophilic compounds. They offer a broad range of HILIC products under the brand names of iHILIC®-Fusion, iHILIC®-Fusion(+), iHILIC®-Fusion(P), and iSPE®-HILIC.
Tanomed has developed a unique nasal spray to relieve and prevent the progression of the common cold by reinforcing the body’s own defenses. The patented technology is based on Swedish research carried out in cooperation with Umeå University and with business development support from the Umeå Biotech Incubator. The company was sold to Karo Bio AB in spring 2015.
Obesity is a serious and increasing worldwide problem. Inhibition of the appetite-stimulating factors would be a possible treatment for obesity. This discovery provides a target for possible drug intervention for limiting food intake among the obese. Today the hypothesis still holds and three drug companies have been formed.
MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical need such as prostate, lung, kidney, and endometrial cancer.
Acne vulgaris affects more than 80 percent of people at some point in their life and frequently continues into adulthood. Recent data suggest that there are about 700 million people living with acne around the world. This case focuses on a novel approach to fighting acne without the hazards of antibiotic resistance development.
Our project goals aim at increased survival, improved quality of life and less suffering for cancer patients. Our novel chemical entities (NCE) can prevent over-activation of certain signaling pathways and are based on existing pharmaceuticals that are well tolerable and easy to produce. This will be a first in class drug with little side effects (known drug class), addressing cancer induced cachexia and suppression of the immune system.
InfiCure Bio offer advanced drug validation services for pharmaceutical companies developing drugs against fibrosis – or scar tissue formation in organs. The shortage of existing model systems that reflect human fibrotic disease conditions, make this a very attractive CRO-service for pharmaceutical developers.
Lipum develops a biological pharmaceutical for a novel mechanism of action in the treatment of chronic inflammations. The lead candidate drug (SOL-116) is a monoclonal antibody directed towards the protein bile salt-stimulated lipase, BSSL. One indication is as an orphan drug for the more severe forms of Juvenile Idiopathic Arthritis (JIA), providing patients with an effective treatment alternative having less adverse effects than the drugs used today.
By combining two different methods, Medsens AB is aiming at offering a whole new tool for realtime microdiagnostics during prostate cancer surgery. The company’s instrument is far more accurate that the methods used by clinicians today – which could make surginal procedures much more efficient. The project is based on the work of Olof Lindahl och Kerstin Ramser.
Periodontitis, or gum disease, is both painful and socially stigmatizing. Anders Johansson and his team identified a plant extract with the ability to neutralize the A. actinomycetemcomitans leucotoxin as a possible solution for a new treatment.
We are developing safe and resistance-breaking molecules that target an enzyme essential for nerve signaling in mosquitoes via a new mode of action. In contrast to current insecticides, we have designed our molecules to specifically target mosquitoes, without affecting other organisms.
Brain stimulation offer digital evidence-based virtual reality rehabilitation for improved quality of life for stroke patients. We offer an accessible treatment strategy for patients suffering from neglect with shorter stay at hospital and eventually less need of support in their daily life.
Protest diagnostics offers the next generation of doping tests – rapid and accurate detection of blood doping through a molecular fingerprint. The company provides analytical services for blood, urine, saliva and skeletal muscle tissue. Protest diagnostics also has close collaboration with Waters Ltd.
We are developing an oral patch, with a pending patented galenic formulation, providing immediate pain relief. The product can theoretically reach a target patient population of 10-20,000 patients annually in Sweden, and considerably higher in international markets.